Dry Eye Rescue Is Offering Friends Of MDA A 20% Discount On All Products To Help With Your Eye Conditions

Click Here To Save Now

Resources

Feb 11, 2026

Patients may need help accessing new dry eye therapies

By: Kenneth A. Beckman, MD, FACS By: Kourtney H. Houser, MD By: Nandini Venkateswaran, MD By: Alex Young Fact checked by: Christine Klimanskis, ELS Welcome to another edition of CEDARS/ASPENS…

Patients may need help accessing new dry eye therapies

Feb 11, 2026

A Massive Wave of Eye Disease is Coming, and Healthcare is Unprepared

By: Landon Grace The cruel irony is that incredibly effective treatments already exist. Many people, however, cannot access them due to barriers to care A public health crisis is brewing…

A Massive Wave of Eye Disease is Coming, and Healthcare is Unprepared

Feb 10, 2026

February is Macular Degeneration & Low Vision Month.

 The Macular Degeneration Association is proud to sharethis important information. Age-related macular degeneration (AMD) is the main cause of severe vision loss. There is approximately 20 million Americans aged 40…

February is Macular Degeneration & Low Vision Month.

Feb 6, 2026

Study Adds Fuel to the Debate Over Cataract Surgery and Wet AMD

Earlier concerns about surgery accelerating AMD progression likely overstated, researcher says by Randy Dotinga, Contributing Writer, MedPage Today Key Takeaways There’s been extensive debate over the risk of neovascular age-related macular…

Study Adds Fuel to the Debate Over Cataract Surgery and Wet AMD

Feb 4, 2026

Older than dinosaurs/ Greenland sharks, the unknown treasure. Their eyes could offer the cure for…

2026-01-18 20:42:19 /MISTERE & KURIOZITETE A recent study in Nature Communications and Smithsonian magazine confirms: the rulers of the Arctic seas are the longest-lived vertebrates in the world. And their…

Older than dinosaurs/ Greenland sharks, the unknown treasure. Their eyes could offer the cure for…

Feb 4, 2026

Coping with Macular Degeneration

By Dr. Russel Lazarus Over 40% of people diagnosed with macular degeneration suffer from depression. Macular degeneration, also known as age-related macular degeneration (AMD), is a progressive eye disease that…

Coping with Macular Degeneration

Feb 4, 2026

Multivitamins, mortality, and longevity: Growing data for the ongoing debate

By Lisa Marie Basile | Fact-checked by Davi Sherman Industry Buzz You might build up too much iron or niacin from a daily [MV]… If you want to be healthy, the healthiest form of a…

Multivitamins, mortality, and longevity: Growing data for the ongoing debate

Jan 27, 2026

Seeing the difference: Multimodal imaging for AMD and GA

Author(s):Jeremiah Brown Jr, MD, MS, FASRS Fact checked by: Sheryl Stevenson Key Takeaways Accurate diagnosis of retinal diseases is vital for effective treatment, especially with new therapies for GA and IRDs.…

Seeing the difference: Multimodal imaging for AMD and GA

Jan 27, 2026

Ocugen releases positive preliminary 12-month data from phase 2 ArMaDa trial

Author(s): Martin David Harp Fact checked by: Tracy Ann Politowicz Key Takeaways OCU410 gene therapy showed significant lesion growth reduction in phase 2 trial for geographic atrophy secondary to dry AMD.…

Ocugen releases positive preliminary 12-month data from phase 2 ArMaDa trial

Jan 27, 2026

Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

Recuiting Phase 3 ClinicalTrials.gov IDNCT07007065 SponsorAbbVie Information Provided byABBVIE INC. Study Start (Actual)2025-11-05 Primary Completion (Estimated) 2033-03 Study Completion (Estimated)2033-03 Enrollment (Estimated)561 Study TypeInterventional Last Update Posted2026-01-23 Study Overview Brief Summary…

Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

Jan 8, 2026

PINPOINT Patient Recruiting- Study Invite

Do you have nAMD, DME, or DR? Pinpoint Patient Recruiting, a market research recruitment company, is recruiting people who have been diagnosed with diabetic retinopathy (DR), diabetic macular edema (DME),…

PINPOINT Patient Recruiting- Study Invite

Jan 7, 2026

New iCare Home2 tonometer detects IOP patterns, variations, out-of-office spikes

By: Justin Cooper Fact checked by: Christine Klimanskis, ELS Key takeaways: Most patients used the iCare Home2 device multiple times per day. The device captures daily IOP fluctuations that occur…

New iCare Home2 tonometer detects IOP patterns, variations, out-of-office spikes

Jan 6, 2026

5 Resolutions Eye Doctors Want You to Have for 2026

CU Anschutz eye specialists share easy habits to help protect your eyes and vision. by: Tayler Shaw | January 5, 2026 With the start of 2026, a top resolution for many…

5 Resolutions Eye Doctors Want You to Have for 2026

Jan 6, 2026

Study: Ellipsoid zone a clinically relevant endpoint in AMD, GA trials

By:Arshad M. Khanani, MD, MA, FASRS By:Anthony DeFino Fact checked by:Christine Klimanskis, ELS   Key takeaways: A study found a correlation between ellipsoid zone loss and best-corrected visual acuity. EZ…

Study: Ellipsoid zone a clinically relevant endpoint in AMD, GA trials

Jan 6, 2026

Eye-opening research

Dorota Skowronska-Krawczyk’s astonishing findings about Greenland sharks may lead to new ways of preserving vision as we age By: Cynthia Rebolledo, UC Irvine Dorota Skowronska-Krawczyk sits in her office, eyes…

Eye-opening research

Jan 2, 2026

A new treatment round-up for AMD and GA

Author(s) by: Sheila Setork, OD Fact checked by: Kirsty Mackay Age-related macular degeneration (AMD) is one of the main causes of irreversible vision loss in older individuals, affecting approximately 20 million…

A new treatment round-up for AMD and GA

Dec 30, 2025

Besides the gut, what other microbiomes in the body affect eye health and disease?

By: Michela Cimberle By: John Danias, MD, PhD By: Stefano Barabino, MD, PhD Fact checked by: Christine Klimanskis, ELS Oral microbiome In the complex, multifactorial pathophysiology of glaucoma, as in most…

Besides the gut, what other microbiomes in the body affect eye health and disease?

Dec 30, 2025

FDA approves Nufymco as biosimilar to Lucentis

By: Anthony DeFino Fact checked by: Eamon N. Dreisbach Key takeaways: Nufymco is indicated for the treatment of patients with a number of retinal diseases. The VEGF inhibitor is the…

FDA approves Nufymco as biosimilar to Lucentis

Dec 22, 2025

Light Therapy for Dry AMD: What Do We Know?

Newly authorized treatment has fans, but skepticism persists amid sparse data by Randy Dotinga, Contributing Writer, MedPage Today December 19, 2025 • 4 min read Armed with a recent authorization from…

Light Therapy for Dry AMD: What Do We Know?

Dec 19, 2025

Can a retinal implant reverse macular degeneration?

Researchers at the USC Roski Eye Institute, part of Keck Medicine of USC, are launching a phase 2b clinical trial examining if stem cells bioengineered to replace failing cells in the retina damaged by…

Can a retinal implant reverse macular degeneration?

Dec 18, 2025

Role of B Vitamins in Preventing the Development and Progression of Age-Related Macular Degeneration

by: Julie Poteet, Cecelia Koetting &  Priya S. Vakharia Abstract No current treatments are curative for age-related macular degeneration (AMD), and preventing disease progression is challenging. Dietary factors play a role in…

Role of B Vitamins in Preventing the Development and Progression of Age-Related Macular Degeneration

Dec 18, 2025

Holiday Break

Dear friends, We want to let you know that the Macular Degeneration Association will be taking a short holiday break! We’ll be closed from December 24, 2025, to January 1,…

Holiday Break

Dec 15, 2025

Regeneron Pharmaceuticals is currently sponsoring a clinical trial enrolling patients with geographic atrophy (GA) who qualif

Regeneron has partnered with The Foundation Fighting Blindness to raise awareness about an ongoing clinical trial investigating subcutaneously administered investigational medicines as potential treatments for geographic atrophy (GA). The study…

Regeneron Pharmaceuticals is currently sponsoring a clinical trial enrolling patients with geographic atrophy (GA) who qualif

Dec 9, 2025

ONL Therapeutics reports positive phase 1b data for xelafaslatide in geographic atrophy

Author(s): Martin David Harp Key Takeaways Xelafaslatide, a Fas inhibitor, shows promise in protecting retinal cells and slowing GA progression in dry AMD. The phase 1b study evaluated safety and…

ONL Therapeutics reports positive phase 1b data for xelafaslatide in geographic atrophy

Dec 9, 2025

Supporting eye health through a holistic approach to full-body health

Author(s):Vittorio Mena, OD, MS, Fact checked by: Matt Hoffman, Kirsty Mackay Our patients benefit from a preventive approach that includes lifestyle adjustment, nutrition, and supplementation. Eyes are an integral part of overall…

Supporting eye health through a holistic approach to full-body health

Dec 9, 2025

Majority of US patients with dry eye experience symptoms weekly, survey finds

Author(s): Jordana Joy, Associate Editor Fact checked by: Ron Panarotti The survey was conducted by OnePoll on October 2025 and included 1000 US patients with dry eye. Key takeaways Dry eye…

Majority of US patients with dry eye experience symptoms weekly, survey finds

Dec 3, 2025

Thank you-#GivingTuesday

Thank you to all who participated in yesterday’s # GivingTuesday. Your support fuels vital research and inspires hope for a brighter future.

Thank you-#GivingTuesday

Dec 1, 2025

Judi Dench Says She ‘Can’t Recognize Anybody’ Due to Eye Condition: ‘I Can’t See Anymore’

by: Jack Dunn Judi Dench recently shared that she “can’t recognize anybody” due to her eye condition. When asked by ITV why she’s stepped away from acting, Dench told the outlet, “I can’t…

Judi Dench Says She ‘Can’t Recognize Anybody’ Due to Eye Condition: ‘I Can’t See Anymore’

Dec 1, 2025

#GivingTuesday 2025

Join us for #GivingTuesday2025 on Tuesday, December 2nd, from 12:00 AM to 11:59 PM! Your generous support can make a transformative impact in our fight against macular degeneration. Together, we…

#GivingTuesday 2025

Nov 26, 2025

Happy Thanksgiving

Happy Thanksgiving! The Macular Degeneration Association would like to express our gratitude for your support and thoughtfulness. “As we show our appreciation, we must remember that the highest form of…

Happy Thanksgiving

Newsletter Sign-up

  • This field is for validation purposes and should be left unchanged.